CytoDyn Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jay Lalezari

Amministratore delegato

US$815.7k

Compenso totale

Percentuale dello stipendio del CEO	18.7%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.2yrs
Durata media del Consiglio di amministrazione	2.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jay Lalezari rispetto agli utili di CytoDyn?
Data	Compenso totale	Stipendio	Guadagni aziendali
Aug 31 2024	n/a	n/a	-US$21m
May 31 2024	US$816k	US$152k	-US$51m

Compensazione vs Mercato: La retribuzione totale di Jay ($USD 745.69K ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.54M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Jay con le performance aziendali.

AMMINISTRATORE DELEGATO

Jay Lalezari (64 yo)

less than a year

Mandato

US$815,685

Compensazione

Dr. Jacob P. Lalezari, also known as Jay, MD, was Interim Chief Executive Officer at CytoDyn Inc. since November 17, 2023 until January 26, 2024 and serves as it's Chief Executive Officer and principal exe...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jacob Lalezari	CEO & Member of Scientific Advisory Board	less than a year	US$815.69k	Nessun dato
Mitchell Cohen	Interim Chief Financial Officer	less than a year	US$655.20k	Nessun dato
Tyler Blok	Chief Legal Officer & Corporate Secretary	1.2yrs	US$575.83k	0.000020% $ 32.4
Cyrus Arman	Senior Vice President of Business Operations	1.3yrs	US$387.59k	0.036% $ 57.8k
Bernie Cunningham	Vice President of Operations	2.1yrs	Nessun dato	Nessun dato
Scott Hansen	Head of Research & Basic Science	1.8yrs	Nessun dato	Nessun dato
Max Lataillade	Senior VP & Head of Clinical Development	no data	Nessun dato	Nessun dato
Cristina De Leon	Investors	no data	Nessun dato	Nessun dato

1.2yrs

Durata media

53.5yo

Età media

Gestione esperta: Il team dirigenziale di CYDY non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jacob Lalezari	CEO & Member of Scientific Advisory Board	no data	US$815.69k	Nessun dato
Stephen Simes	Independent Director	2yrs	US$201.80k	0% $ 0
Karen Brunke	Independent Director	2.5yrs	US$184.30k	0% $ 0
Hope Rugo	Member of Scientific Advisory Board	4.1yrs	Nessun dato	Nessun dato
Ryan Dunlap	Independent Director	2.2yrs	US$201.80k	0% $ 0
Tanya Urbach	Independent Chairman of the Board	2.9yrs	US$234.30k	0.013% $ 21.6k
Jonah Sacha	Member of Scientific Advisory Board	6.6yrs	Nessun dato	Nessun dato
Mazen Noureddin	Member of Scientific Advisory Board	4.1yrs	Nessun dato	Nessun dato
Lishomwa Ndhlovu	Independent Director	2.9yrs	US$181.80k	0% $ 0
Jordan Lake	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Naoto Ueno	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Otto Yang	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

2.9yrs

Durata media

60.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CYDY non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.

CytoDyn Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CytoDyn Inc., Annual General Meeting, Nov 22, 2024

CytoDyn Appoints Max Lataillade as Senior Vice President and Head of Clinical Development

CytoDyn Inc. Announces Appointment of Jacob Lalezari as CEO

CytoDyn Inc. Appoints Jacob Lalezari M.D. as Interim CEO

CytoDyn Inc., Annual General Meeting, Nov 09, 2023

CytoDyn Inc. Announces CEO Changes

Recent updates

CytoDyn Inc., Annual General Meeting, Nov 22, 2024

CytoDyn Appoints Max Lataillade as Senior Vice President and Head of Clinical Development

CytoDyn Inc. Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer

CytoDyn Inc. and SMC Laboratories, Inc. Announce Start of Preclinical MASH Study

CytoDyn Inc. Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

CytoDyn Inc. Announces Appointment of Jacob Lalezari as CEO

CytoDyn Inc. Announces Lawsuit Update

CytoDyn Inc. Appoints Jacob Lalezari M.D. as Interim CEO

CytoDyn Inc. announced delayed 10-Q filing

CytoDyn Inc., Annual General Meeting, Nov 09, 2023

CytoDyn Inc. announced delayed annual 10-K filing

CytoDyn Inc. Announces CEO Changes

CytoDyn Inc. Announces Executive Changes

CytoDyn Inc. Announces Resignation of Scott A. Kelly, Chief Medical Officer

Nitya G. Ray Resigns as Chief Technology Officer of CytoDyn Inc

CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

CytoDyn Inc., Annual General Meeting, Dec 09, 2022

CytoDyn Inc. Announces Board Changes

CytoDyn Inc. Approves the Appointment of Ryan Dunlap as Director

CytoDyn Inc. announced delayed annual 10-K filing

CytoDyn Inc. Appoints Cyrus Arman as President

CytoDyn Inc. Announces Preclinical Study in Nonhuman Primates That Will Evaluate the Potential Use in HIV of a Gene Therapy Based on the Experimental Monoclonal Antibody Leronlimab

CytoDyn Inc. Announces Resignation of Jordan G. Naydenov as Board member

CytoDyn Inc. announced that it expects to receive $4.785 million in funding

CytoDyn Inc. Announces Executive Changes

CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program

CytoDyn Inc. Announces Research Paper Published Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 from Heavily Treatment Experienced Subjects

CytoDyn Inc. Announces Positive Results from the 350 Mg Weekly Dose of Its Phase 2 NASH Clinical Trial

CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population

ytoDyn Inc. Announces Additional Preliminary Results to Date from 20 Patients Who Have Completed Open-Label Portion of Phase 2 Trial for NASH

CytoDyn Inc. Submits Protocol with FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population

Cytodyn’S Cro in Brazil Met with Anvisa to Modify Cd16 Trial for Critically Ill Covid-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022

CytoDyn Inc. Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission

CytoDyn Inc. Reports Data from Its Trial Treating NASH Open Label with Leronlimab

CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade

CytoDyn Inc. Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with Iv Administration of Four Doses (700Mg/Week)

Group of CytoDyn Inc. Stockholders Announces Federal Court Dismisses Litigation Brought by Company

Paul A. Rosenbaum Provides Information to Shareholders of CytoDyn

CytoDyn Inc. Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms

CytoDyn Inc. announced that it has received $3.872 million in funding

Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees

CytoDyn Inc. Updates Preliminary Results from Phase 1B/2 Trials

CytoDyn Provides Update on Rosenbaum and Patterson Group Litigation

Paul A. Rosenbaum Provides Information to the Shareholders

Paul A. Rosenbaum Provides Information to the Shareholders

CytoDyn Inc. Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

Paul Rosenbaum Issues a Statement to Press Outlets

CytoDyn Inc. Announces Preliminary Results from 30 Mtnbc Patients Treated with Leronlimab

CytoDyn Inc. Announces Advance from Phase 1B to Phase 2 Trial of Its Clinical Trial with Leronlimab in Combination with Carboplatin for the Treatment of Metastatic Triple-Negative Breast Cancer

CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV

CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms

CytoDyn Inc. Announces Publication in Nature Communications of A Study Showing leronlimab Preventing HIV Infection in Primate

CytoDyn Inc. Conducting a Phase 2 Clinical Trial for nonalcoholic steatohepatitis to Evaluate the Effect of Leronlimab on Liver Steatosis and Fibrosis

CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and Philippines

Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against CytoDyn, Inc

CytoDyn Inc. announces HIV Indication Update

The Portnoy Law Firm Announces Last Days to Participate Actively in the Class Action Lawsuit Against CytoDyn, Inc

CytoDyn Inc. announced that it has received $25 million in funding

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against CytoDyn, Inc

CytoDyn Inc. Appoints Christopher P. Recknor as Chief Operating Officer

CytoDyn Inc.’s Long-Haulers COVID-19 Trial Enrolled 20 Patients Within 10 Days

CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, March 8

CytoDyn Inc.'s Phase 3 Trial Demonstrates Safety, A 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill Covid-19 Patients Treated with Leronlimab

CytoDyn Inc. in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients

Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit to Access Cytodyn’s Leronlimab for Covid-19 Patients

FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients

FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 Trial

CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19

CytoDyn Inc. Announces First Patient Enrolled in Phase 2 Trial for Nash